Brokerages Set Insmed, Inc. (NASDAQ:INSM) PT at $210.95

Shares of Insmed, Inc. (NASDAQ:INSM) have been given a consensus recommendation of “Moderate Buy” by the twenty-five research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, twenty-three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $210.9545.

Several equities research analysts have issued reports on the stock. Guggenheim lowered their target price on shares of Insmed from $230.00 to $226.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Roth Mkm reissued a “buy” rating and set a $212.00 price target on shares of Insmed in a research report on Friday, April 17th. Royal Bank Of Canada lowered their price target on shares of Insmed from $220.00 to $205.00 and set an “outperform” rating on the stock in a research report on Friday, May 8th. Stifel Nicolaus boosted their price target on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, Barclays boosted their price target on shares of Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a research report on Wednesday, April 1st.

Insmed Price Performance

Insmed stock opened at $108.37 on Friday. The company’s fifty day moving average price is $135.14 and its 200 day moving average price is $158.47. Insmed has a 1 year low of $65.56 and a 1 year high of $212.75. The stock has a market capitalization of $23.49 billion, a P/E ratio of -18.85 and a beta of 0.89. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. During the same quarter last year, the company earned ($1.42) EPS. The firm’s revenue for the quarter was up 229.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Insmed will post -2.52 earnings per share for the current fiscal year.

Insider Activity at Insmed

In related news, insider Michael Alexander Smith sold 6,149 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $108.47, for a total value of $666,982.03. Following the sale, the insider directly owned 41,613 shares in the company, valued at approximately $4,513,762.11. The trade was a 12.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the sale, the chief operating officer owned 106,810 shares in the company, valued at approximately $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 156,643 shares of company stock worth $24,513,766. Company insiders own 2.10% of the company’s stock.

Institutional Trading of Insmed

Institutional investors and hedge funds have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC raised its holdings in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the period. CoreCap Advisors LLC purchased a new stake in Insmed in the 4th quarter valued at about $27,000. SBI Securities Co. Ltd. raised its holdings in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares during the period. GraniteShares Advisors LLC purchased a new stake in Insmed during the fourth quarter worth about $30,000. Finally, Reflection Asset Management purchased a new stake in Insmed during the fourth quarter worth about $30,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.